Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells

Zhaowei Meng, Norisato Mitsutake, Masahiro Nakashima, Dmytro Starenki, Michiko Matsuse, Shu Takakura, Hiroyuki Namba, Vladimir Saenko, Kazuo Umezawa, Akira Ohtsuru, Shunichi Yamashita

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Nuclear factor κB (NF-κB), as an antiapoptotic factor, crucially affects the outcomes of cancer treatments, being one of the major culprits of resistance to chemotherapy. In this study, we investigated whether dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can enhance antitumor activities of taxanes in anaplastic thyroid cancer (ATC) cells. Taxanes induced NF-κB activation in ATC cells, which could compromise the therapeutic effect of the drugs. However, DHMEQ, by inhibiting the nuclear translocation of NF-κB, completely suppressed the DNA binding capacities of NF-κB and lowered the levels of nuclear NF-κB protein. Compared with single treatment (either taxane or DHMEQ), the combined treatment strongly potentiated apoptosis, confirmed by cell survival assay; Western blotting for poly (ADPribose) polymerase, caspase 3, X-linked inhibitor of apoptosis, and survivin; and flow cytometry for annexin V. Furthermore, we also demonstrate for the first time that the combined treatment showed significantly greater inhibitory effect on tumor growth in a nude mice xenograft model. These findings suggest that taxanes are able to induce NF-κB activation in ATC cells, which could attenuate antitumor activities of the drugs, but inhibition of NF-κB by DHMEQ creates a chemosensitive environment and greatly enhances apoptosis in taxanes-treated ATC cells in vitro and in vivo. Thus, DHMEQ may emerge as an attractive therapeutic strategy to enhance the response to taxanes in ATCs.

Original languageEnglish
Pages (from-to)5357-5365
Number of pages9
JournalEndocrinology
Volume149
Issue number11
DOIs
Publication statusPublished - Nov 1 2008
Externally publishedYes

Fingerprint

Taxoids
Apoptosis
Poly(ADP-ribose) Polymerases
Annexin A5
Therapeutic Uses
Therapeutics
Heterografts
Nude Mice
Caspase 3
Antineoplastic Agents
Neoplasms
Cell Survival
Flow Cytometry
Western Blotting
Anaplastic Thyroid Carcinoma
dehydroxymethylepoxyquinomicin
Drug Therapy
DNA
Growth
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology

Cite this

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. / Meng, Zhaowei; Mitsutake, Norisato; Nakashima, Masahiro; Starenki, Dmytro; Matsuse, Michiko; Takakura, Shu; Namba, Hiroyuki; Saenko, Vladimir; Umezawa, Kazuo; Ohtsuru, Akira; Yamashita, Shunichi.

In: Endocrinology, Vol. 149, No. 11, 01.11.2008, p. 5357-5365.

Research output: Contribution to journalArticle

Meng, Z, Mitsutake, N, Nakashima, M, Starenki, D, Matsuse, M, Takakura, S, Namba, H, Saenko, V, Umezawa, K, Ohtsuru, A & Yamashita, S 2008, 'Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells', Endocrinology, vol. 149, no. 11, pp. 5357-5365. https://doi.org/10.1210/en.2008-0279
Meng, Zhaowei ; Mitsutake, Norisato ; Nakashima, Masahiro ; Starenki, Dmytro ; Matsuse, Michiko ; Takakura, Shu ; Namba, Hiroyuki ; Saenko, Vladimir ; Umezawa, Kazuo ; Ohtsuru, Akira ; Yamashita, Shunichi. / Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. In: Endocrinology. 2008 ; Vol. 149, No. 11. pp. 5357-5365.
@article{2adbfd8cc5584fa8be11a5b7117f2d3a,
title = "Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells",
abstract = "Nuclear factor κB (NF-κB), as an antiapoptotic factor, crucially affects the outcomes of cancer treatments, being one of the major culprits of resistance to chemotherapy. In this study, we investigated whether dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can enhance antitumor activities of taxanes in anaplastic thyroid cancer (ATC) cells. Taxanes induced NF-κB activation in ATC cells, which could compromise the therapeutic effect of the drugs. However, DHMEQ, by inhibiting the nuclear translocation of NF-κB, completely suppressed the DNA binding capacities of NF-κB and lowered the levels of nuclear NF-κB protein. Compared with single treatment (either taxane or DHMEQ), the combined treatment strongly potentiated apoptosis, confirmed by cell survival assay; Western blotting for poly (ADPribose) polymerase, caspase 3, X-linked inhibitor of apoptosis, and survivin; and flow cytometry for annexin V. Furthermore, we also demonstrate for the first time that the combined treatment showed significantly greater inhibitory effect on tumor growth in a nude mice xenograft model. These findings suggest that taxanes are able to induce NF-κB activation in ATC cells, which could attenuate antitumor activities of the drugs, but inhibition of NF-κB by DHMEQ creates a chemosensitive environment and greatly enhances apoptosis in taxanes-treated ATC cells in vitro and in vivo. Thus, DHMEQ may emerge as an attractive therapeutic strategy to enhance the response to taxanes in ATCs.",
author = "Zhaowei Meng and Norisato Mitsutake and Masahiro Nakashima and Dmytro Starenki and Michiko Matsuse and Shu Takakura and Hiroyuki Namba and Vladimir Saenko and Kazuo Umezawa and Akira Ohtsuru and Shunichi Yamashita",
year = "2008",
month = "11",
day = "1",
doi = "10.1210/en.2008-0279",
language = "English",
volume = "149",
pages = "5357--5365",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells

AU - Meng, Zhaowei

AU - Mitsutake, Norisato

AU - Nakashima, Masahiro

AU - Starenki, Dmytro

AU - Matsuse, Michiko

AU - Takakura, Shu

AU - Namba, Hiroyuki

AU - Saenko, Vladimir

AU - Umezawa, Kazuo

AU - Ohtsuru, Akira

AU - Yamashita, Shunichi

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Nuclear factor κB (NF-κB), as an antiapoptotic factor, crucially affects the outcomes of cancer treatments, being one of the major culprits of resistance to chemotherapy. In this study, we investigated whether dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can enhance antitumor activities of taxanes in anaplastic thyroid cancer (ATC) cells. Taxanes induced NF-κB activation in ATC cells, which could compromise the therapeutic effect of the drugs. However, DHMEQ, by inhibiting the nuclear translocation of NF-κB, completely suppressed the DNA binding capacities of NF-κB and lowered the levels of nuclear NF-κB protein. Compared with single treatment (either taxane or DHMEQ), the combined treatment strongly potentiated apoptosis, confirmed by cell survival assay; Western blotting for poly (ADPribose) polymerase, caspase 3, X-linked inhibitor of apoptosis, and survivin; and flow cytometry for annexin V. Furthermore, we also demonstrate for the first time that the combined treatment showed significantly greater inhibitory effect on tumor growth in a nude mice xenograft model. These findings suggest that taxanes are able to induce NF-κB activation in ATC cells, which could attenuate antitumor activities of the drugs, but inhibition of NF-κB by DHMEQ creates a chemosensitive environment and greatly enhances apoptosis in taxanes-treated ATC cells in vitro and in vivo. Thus, DHMEQ may emerge as an attractive therapeutic strategy to enhance the response to taxanes in ATCs.

AB - Nuclear factor κB (NF-κB), as an antiapoptotic factor, crucially affects the outcomes of cancer treatments, being one of the major culprits of resistance to chemotherapy. In this study, we investigated whether dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can enhance antitumor activities of taxanes in anaplastic thyroid cancer (ATC) cells. Taxanes induced NF-κB activation in ATC cells, which could compromise the therapeutic effect of the drugs. However, DHMEQ, by inhibiting the nuclear translocation of NF-κB, completely suppressed the DNA binding capacities of NF-κB and lowered the levels of nuclear NF-κB protein. Compared with single treatment (either taxane or DHMEQ), the combined treatment strongly potentiated apoptosis, confirmed by cell survival assay; Western blotting for poly (ADPribose) polymerase, caspase 3, X-linked inhibitor of apoptosis, and survivin; and flow cytometry for annexin V. Furthermore, we also demonstrate for the first time that the combined treatment showed significantly greater inhibitory effect on tumor growth in a nude mice xenograft model. These findings suggest that taxanes are able to induce NF-κB activation in ATC cells, which could attenuate antitumor activities of the drugs, but inhibition of NF-κB by DHMEQ creates a chemosensitive environment and greatly enhances apoptosis in taxanes-treated ATC cells in vitro and in vivo. Thus, DHMEQ may emerge as an attractive therapeutic strategy to enhance the response to taxanes in ATCs.

UR - http://www.scopus.com/inward/record.url?scp=54349105133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349105133&partnerID=8YFLogxK

U2 - 10.1210/en.2008-0279

DO - 10.1210/en.2008-0279

M3 - Article

C2 - 18653704

AN - SCOPUS:54349105133

VL - 149

SP - 5357

EP - 5365

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -